SCHEMBL1481672

SCHEMBL1481672

CCn1cc(-c2ccc(Cl)cc2Cl)nc1C=Cc1ccc(-c2cccc(O)c2)cc1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.35
TP53 P04637 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
DPP4 P27487 2/20 0.33
DPP8 Q6V1X1 2/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
CA12 O43570 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
HSD17B1 P14061 2/20 0.33
HSD17B2 P37059 2/20 0.33
LMNA P02545 1/20 0.32
PDE4B Q07343 3/20 0.32
PPARG P37231 1/20 0.32
PIK3CA P42336 1/20 0.32
KCNA3 P22001 1/20 0.32
ADORA2A P29274 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481670 1.00 MAPT (0.35) MAPTTP53MEN1KMT2ASMN1; SMN2
SCHEMBL1480554 0.92 MEN1 (0.40) MAPTMEN1KMT2ASMN1; SMN2DPP4
SCHEMBL1480556 0.92 MEN1 (0.40) MAPTMEN1KMT2ASMN1; SMN2DPP4
SCHEMBL1481423 0.86 LMNA (0.35) MAPTMEN1KMT2ASMN1; SMN2DPP4
SCHEMBL1481420 0.86 LMNA (0.35) MAPTMEN1KMT2ASMN1; SMN2DPP4
SCHEMBL1480942 0.86 MEN1 (0.41) MAPTTP53MEN1KMT2ASMN1; SMN2
SCHEMBL1480940 0.86 MEN1 (0.41) MAPTTP53MEN1KMT2ASMN1; SMN2
SCHEMBL1481692 0.85 MAPT (0.41) MAPTMEN1KMT2ASMN1; SMN2DPP4
SCHEMBL1481688 0.85 MAPT (0.41) MAPTMEN1KMT2ASMN1; SMN2DPP4
SCHEMBL1481086 0.83 FFAR4 (0.39) PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885TP53 1088/4885MEN1 3467/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885TP53 1088/4885MEN1 3467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.